| Popis: |
Objectives: This study aims to evaluate the demographic characteristics, maternal and neonatal outcomes of pregnant women receivingcardiovascular medications (CVMs) during pregnancy and admitted to the Teratogenicity Information Service (TIS).Patients and methods: In this descriptive, cross-sectional, retrospective study, a total of 47 pregnant women (mean age: 34.0±5.5 years;range, 19 to 41 years) who were admitted to the TIS of Dokuz Eylul University were included between January 2014 and December 2016.Demographic characteristics, types of the CVMs, concomitant medication and/or substance use, medical and obstetric histories of cases,and maternal and neonatal outcomes were evaluated.Results: The most commonly used drugs were beta-receptor antagonists. The mean gestational age at the time of delivery was 35.9±8.2weeks and 42 infants (89.4%) were healthy. Five pregnancies (10.6%) ended in miscarriage or elective termination. No malformation wasfound in healthy live newborns.Conclusion: The use of CVMs during pregnancy remains as a challenging issue, as their potential effects on the developing fetus are notfully known. Based on these study results, it is difficult to determine safety of CVMs during pregnancy and establish a causal relationshipbetween maternal/neonatal outcomes and CVMs exposure.Keywords: Cardiovascular system medicines, maternal and neonatal outcomes, pregnancy. |
